Data to be Presented Next Week in Late-Breaking Poster at AASLD Annual Meeting LOUISVILLE, Colo., Oct. 28, 2008 – GlobeImmune Inc. today announced that four-week data from the on-going Phase 2 clinical trial for GI-5005, the Company’s therapeutic vaccine candidate … Continue reading
GlobeImmune HCV Phase 2 Four-week Clinical Trial Data for GI-5005 to be Highlighted at the AASLD President’s Press Conference
October 28, 2008